Insider Selling: Beigene, Ltd. (NASDAQ:ONC) CEO Sells $14,596,526.70 in Stock

Beigene, Ltd. (NASDAQ:ONC) CEO John Oyler sold 58,590 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $249.13, for a total transaction of $14,596,526.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

John Oyler also recently made the following trade(s):

• On Monday, March 3rd, John Oyler sold 101,000 shares of Beigene stock. The stock was sold at an average price of $244.30, for a total value of $24,674,300.00.

Beigene Price Performance

Shares of Beigene stock opened at $247.07 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $287.88. The company has a market capitalization of $24.18 billion, a P/E ratio of -29.98, a P/E/G ratio of 7.73 and a beta of 0.65.

Beigene (NASDAQ:ONC) last released its earnings results on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The firm had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. On average, analysts expect that Beigene, Ltd. will post -5.82 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ONC. Bank of America raised Beigene from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd. Macquarie upped their price target on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.